Contact Integra LifeSciences stock loss lawyer Timothy L. Miles about an Integra LifeSciences class action lawsuit
The Integra LifeScience class action lawsuit seeks to represent purchasers or acquirers of Integra LifeSciences Holdings Corporation (NASDAQ: IART) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”). Captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation, No. 23-cv-20321 (D.N.J.), the Integra LifeSciences class action lawsuit charges Integra LifeSciences and certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.
If you suffered losses in Integra LifeSciences stock and wish to serve as lead plaintiff in the Integra LifeScience class action lawsuit, please contact Integra LifeSciences Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at [email protected] or by submitting a contact form.
Lead plaintiff motions for the Integra LifeSciences class action lawsuit must be filed with the court no later than November 13, 2023.
Read on for answers to five frequently asked questions about the Integra LifeScience class action lawsuit.
what are the ALLEGATIONS IN THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT?
Integra LifeSciences develops regenerative tissue technologies and neurological solutions. The Integra LifeSciences class action lawsuit alleges that on November 2, 2018, the U.S. Food and Drug Administration (“FDA”) issued a Notice of Inspectional Observations on Form 483 (the “2018 Form 483”) to put Integra LifeSciences on notice of quality systems and manufacturing conditions violations. The complaint further alleges that on March 6, 2019, the FDA issued a warning letter (the “2019 Warning Letter”) to Integra LifeSciences further documenting the quality control and manufacturing problems at its Boston, Massachusetts facility (“Boston Facility”). On November 12, 2021, the FDA issued another Form 483 (the “2021 Form 483”) for violations of good manufacturing practice requirements, the complaint further alleges.
The Integra LifeScience class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Integra LifeSciences failed to take sufficient measures to remediate the violations identified by the FDA in the 2018 Form 483, 2019 Warning Letter, and the 2021 Form 483; (ii) as a result of those deficiencies, since March 2018, all products manufactured in the Boston Facility had the potential for higher-than-permitted levels of endotoxin and would need to be recalled; and (iii) Integra LifeSciences was not making progress towards obtaining its premarket approval (“PMA”) indication for its product SurgiMend, in part, because the manufacturing site that would produce the PMA product was in continued violation of the FDA standards that Integra LifeSciences failed to rectify years after the initial notice of the violations.
The Integra LifeSciences class action lawsuit further alleges that on April 26, 2023, Integra LifeSciences disclosed that it had “[p]aused production at the Boston manufacturing site in March while pulling forward quality system upgrades project.” As a result of the shutdown, Integra LifeSciences announced lowered operating margins for the quarter and flat revenue growth projection, the complaint alleges. The Integra LifeSciences class action lawsuit alleges that on this news, the price of Integra LifeSciences common stock fell nearly 8%.
The Integra LifeSciences class action lawsuit further alleges that on May 23, 2023, Integra LifeSciences disclosed that “after consultation with the [FDA], [Integra LifeSciences] initiated a voluntary global recall of all products manufactured in its [Boston Facility]” that were “distributed between March 1, 2018 and May 22, 2023.” The complaint further alleges that Integra LifeSciences revised its guidance for the second quarter of 2023, lowering its expectation for revenue by 6% and adjusted earnings per diluted share by 26%, and further revealed that Integra LifeSciences expects to take a $22 million impairment charge at the end of the second quarter of 2023 related to recalled inventory that would have to be written off. The Integra LifeSciences class action lawsuit alleges that on this news, the price of Integra LifeSciences common stock fell more than 20%.
IF I SUFFERED LOSSES IN SUFFERED LOSSES IN INTEGRA LIFESCIENCES STOCK, WHEN CAN I EXPECT TO RECEIVE MY PAYMENT IF THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT SETTLES?
If there is a settlement in the Integra LifeSciences class action lawsuit, you should receive a court-ordered Notice through the mail which will provide a date when the court will hold a final hearing to decide if it will approve the settlement. If your address changed, you may also find lawsuits through sites such as Consumer Action and ClassAction.org along with instructions on how to submit a claim.
The Notice will instruct you what you need to do to file a claim. In some class action settlements, you are automatically submitted and need to do nothing further. However, in others, you may be required to submit more information to proceed such as documentation proving your purchase, such as a receipt or brokerage slip or other evidence that you bought or sold Integra LifeSciences stock during the class period and suffered losses in Integra LifeSciences stock.
The court will hold a final hearing in the Integra LifeSciences class action lawsuit on a date provided in the Notice to decide whether to finally approve the settlement. If the Court finally approves the settlement, and there are no objections or appeals, settlement payments will be mailed to all Participating Class Members within a few months. However, if there are objections or appeals, resolving them can take a significant amount of time, perhaps more than a year to resolve the Integra LifeSciences lawsuit.
IF I SUFFERED LOSSES IN INTEGRA LIFESCIENCES STOCK, WHAT ARE THE BENEFITS OF SERVING AS LEAD PLAINTIFF IN THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT?
Serving as a Lead Plaintiff in the Integra LifeSciences class action lawsuit has several advantages and important benefits including:
Thus, there are numerous benefits and other advantages to serving as lead plaintiff in a class action against Integra LifeSciences if you suffered losses in Integra LifeSciences stock.
HOW WAS THE CLASS PERIOD DETERMINED IN THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT??
In a securities fraud class action such as the Integra LifeSciences class action lawsuit, the class period refers to a period of time in which it is alleged the price of the company’s stock was artificially inflated due to false and misleading statements made by company executives. The class period starts when the company makes an untrue statement of material fact about the company or fails to disclose a material fact necessary to render other statements not misleading. The class period ends when the truth is revealed to the investing public through a corrective disclosure.
In order to be a part of the class in the Integra LifeSciences class action lawsuit, you must have suffered losses in Integra LifeSciences stock by purchasing during the class period when it is alleged the price of the stock was artificially inflated to be included in the class action agianst Integra LifeSciences.
HOW CAN A INTEGRA LIFESCIENCES STOCK LOSS LAWYER HELP ME IF I SUFFERED LOSSES IN INTEGRA LIFESCIENCES STOCK?
An Integra LifeSciences stock loss Lawyer is well-versed in the complex laws that govern the securities industry and litigation and focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals. Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, if they have lost money due to mistakes, incompetence, or fraud by an investment professional. While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discover every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct.
Look for a securities lawyer with experience, high ethical standards, verifiable credentials, and a trustworthy reputation among his peers and the judiciary, as well as testimonials from previous clients and awards and recognitions.
One name that immediately pops up is nationally known and widely respected Nashville stock loss lawyer Timothy L. Miles, who has valuable experience working on some of the nation's largest securities class actions and has received numerous awards, mostly due to his high ethical standards, including most recently being named a Top 25 Class action lawyer by the National Trial Lawyers Association, and has maintained an AV rating in securities litigation from Martindale-Hubble since 2014, a trusted legal rating service for over 130 years and was recently named a 2023 Elite Lawyer of the South by Martindale-Hubble for the fifth year in a row, and was a recipient of Avvo Client's Choice Award in 2021. Therefore, you may start by contacting a trusted, well-respected and ethical securities lawyer such as Mr. Miles.
CONTACT AN INTEGRA LIFESCIENCES STOCK LOSS LAWYER TODAY IF YOU SUFFERED LOSSES IN INTEGRA LIFESCIENCES STOCK ABOUT AN INTEGRA LIFESCIENCESCLASS ACTION LAWSUIT
If you suffered losses in Integra LifeSciences stock, contact Integra LifeSciences stock loss lawyer Timothy L. Miles today for a free case evaluation about an Integra LifeSciences class action lawsuit. Call today and see what an Integra LifeSciences stock loss lawyer can do for you if you suffered losses in Integra LifeSciences stock.
Nashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors,shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association,Class Action: Class Action: Top 9National Trial Lawyers, National Trial Lawyers Association (2023), a superb ratedattorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2022); America’s Most Honored Lawyers 2020 – Top 1% by America’s Most Honored (2020-2022). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more. Please visit our website or call for free anytime.
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr., #247
Brentwood, TN 37027
Phone: (855) 846-6529
Email: [email protected]
HOURS OF OPERATION